The BLAZE-1 trial (randomized, double-blind trial) has witnessed a significant decrease in SARS-CoV-2 viral load among the patients who took bamlanivimabÂ plus etesevimab compared to the placebo group. The hospitalization and death rate were significantly lower with the antibody group compared to the placebo group.

- The most frequently reported adverse events were nausea and diarrhea.

- Infusion-related reactions can be possible with combination therapy. Signs and symptoms of infusion-related reactions include fever, chills, headache, myalgia, confusion, chest pain, breathing difficulty, wheezing, hypoxia, arrhythmia, hypotension, hypertension, nausea, angioedema, throat irritation, and urticaria. If an infusion-related reaction is suspected, consider slowing or stopping the infusion. Supportive care may be given.

- Anaphylaxis or severe hypersensitivity reactions can be possible with bamlanivimab monotherapy or combination therapy. Immediately discontinue the infusion and initiate supportive care.

- Clinical worsening of SARS-CoV2 symptoms like fever, hypoxia, respiratory distress after bamlanivimab monotherapy has been reported. Some of these events required hospitalization.

The following adverse events need to be reported within seven days to the FDA.

- Death

- A life-threatening adverse event

- Inpatient hospitalization

- A significant incapacity

- Medical or surgical intervention to prevent death

- A congenital anomaly